Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Diabetes
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
GLP-1 RAs Reduce Adverse Limb Events in Patients with Diabetes
February 2026
New data show GLP-1 RAs lower amputation, cardiovascular, and mortality risks in diabetes patients with prior limb events.
Read more
19 Sep 2024
Night-Time Light Exposure Linked to Higher Type 2 Diabetes Risk
Circadian rhythm disruption has been strongly linked to the development of Type 2 diabetes.
12 Sep 2024
FLOW Trial Shows Benefit of Semaglutide in Type 2 Diabetes and CKD: EASD 2024
Findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes and chronic kidney disease, were presented at EASD 2024.
12 Sep 2024
Predictors for Weight Loss and Glucose Control with Tirzepatide: EASD 2024
New analysis from the SURPASS-4 trial identifies crucial factors for maintaining blood glucose control and weight loss with tirzepatide in patients with Type 2 diabetes.
12 Sep 2024
Early Control of Gestational Diabetes Reduces Childhood Obesity Risk: EASD 2024
A key study presented at EASD 2024 highlights that rapidly managing blood sugar in pregnant women with gestational diabetes reduces the risk of obesity in their children.
11 Sep 2024
Time-Restricted Eating Improves Glycaemic Control in Adults at Risk of Type 2 Diabetes: EASD 2024
Time-restricted eating, limiting food intake to an 8-hour window, significantly improves blood sugar control in adults at risk of Type 2 diabetes, research from EASD 2024 shows.
11 Sep 2024
Liraglutide Effective for Children with Obesity Aged Under 12 Years: EASD 2024
The SCALE Kids trial has found that weight-loss drug liraglutide is safe and effective for children aged 6 to under 12 years living with obesity.
7 Sep 2024
Meat Consumption Linked to Increased Diabetes Risk
A study has confirmed a significant link between a diet that includes meat consumption and the risk of developing type 2 diabetes.
6 Sep 2024
Chronic Diabetes Complications Tied to Increased Mental Health Risks
A new study has highlighted the strong bidirectional relationship between chronic diabetes complications and mental health disorders in individuals with diabetes.
Loading posts...
« Previous
1
…
21
22
23
24
25
…
42
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View